International Stem Cell Corporation (ISCO)

Market Cap	2.61M +149.9%
Revenue (ttm)	9.51M +3.4%
Net Income	-582.00K
EPS	-0.07
Shares Out	8.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	468
Open	0.3260
Previous Close	0.3300
Day's Range	0.3260 - 0.3260
52-Week Range	0.1170 - 0.5400
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About International Stem Cell

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, Pr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 33
• Stock Exchange: OTCMKTS
• Ticker Symbol: ISCO

Financial Performance

In 2025, International Stem Cell's revenue was $9.10 million, an increase of 0.17% compared to the previous year's $9.09 million. Losses were -$418,000, 100.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 21, 2026

Data Sources Report a data error